home.social

#obesity — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #obesity, aggregated by home.social.

fetched live
  1. Amylyx endocrine drug succeeds in key study for low blood sugar

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
    #NewsBeep #News #Medication #Biotechnology #drugdevelopment #Health #Obesity #research #STAT+ #UK #UnitedKingdom
    newsbeep.com/uk/746759/

  2. 📊 In the NEJM STEP 9 trial, 407 adults with obesity and knee osteoarthritis receiving once-weekly semaglutide lost 13.7% of body weight vs. 3.2% with placebo, with greater reductions in knee pain and improved physical function over 68 weeks. GI events led to discontinuation in 6.7%. #Obesity #Osteoarthritis nejm.org/doi/abs/10.1056/NEJMo

  3. 📊 In the NEJM STEP 9 trial, 407 adults with obesity and knee osteoarthritis receiving once-weekly semaglutide lost 13.7% of body weight vs. 3.2% with placebo, with greater reductions in knee pain and improved physical function over 68 weeks. GI events led to discontinuation in 6.7%. #Obesity #Osteoarthritis nejm.org/doi/abs/10.1056/NEJMo

  4. 📊 In the NEJM STEP 9 trial, 407 adults with obesity and knee osteoarthritis receiving once-weekly semaglutide lost 13.7% of body weight vs. 3.2% with placebo, with greater reductions in knee pain and improved physical function over 68 weeks. GI events led to discontinuation in 6.7%. #Obesity #Osteoarthritis nejm.org/doi/abs/10.1056/NEJMo

  5. 📊 In the NEJM STEP 9 trial, 407 adults with obesity and knee osteoarthritis receiving once-weekly semaglutide lost 13.7% of body weight vs. 3.2% with placebo, with greater reductions in knee pain and improved physical function over 68 weeks. GI events led to discontinuation in 6.7%. nejm.org/doi/abs/10.1056/NEJMo

  6. 📊 In the NEJM STEP 9 trial, 407 adults with obesity and knee osteoarthritis receiving once-weekly semaglutide lost 13.7% of body weight vs. 3.2% with placebo, with greater reductions in knee pain and improved physical function over 68 weeks. GI events led to discontinuation in 6.7%. #Obesity #Osteoarthritis nejm.org/doi/abs/10.1056/NEJMo

  7. Samsung Proposes Offer to Acquire Swiss CDMO Specializing in Peptides

    Samsung Biologics CEO, John Rim, says the PolyPeptide acquisition reinforces the company’s long-term growth strategy by not only…
    #EuropeSays #Korea #KR #SamsungBiologics #bioprocessing #contractmanufacturing #diabetes #IndustryNews #news #obesity #peptides #Samsung
    europesays.com/korea/128407/

  8. europesays.com/ie/648257/ Ozempic does something unexpected to the brain’s hunger neurons #Éire #Health #IE #Ireland #Obesity;Nutrition;WorkplaceHealth;Pharmacology;LanguageAcquisition;NutritionResearch;InfantAndPreschoolLearning;Marijuana

  9. An essay summarizing studies showing bias against obese people by both laypeople and by doctors:

    nutritionfacts.org/blog/weight

    #Health #Obesity #HealthCare

  10. An essay summarizing studies showing bias against obese people by both laypeople and by doctors:

    nutritionfacts.org/blog/weight

    #Health #Obesity #HealthCare

  11. An essay summarizing studies showing bias against obese people by both laypeople and by doctors:

    nutritionfacts.org/blog/weight

    #Health #Obesity #HealthCare

  12. An essay summarizing studies showing bias against obese people by both laypeople and by doctors:

    nutritionfacts.org/blog/weight

    #Health #Obesity #HealthCare

  13. An essay summarizing studies showing bias against obese people by both laypeople and by doctors:

    nutritionfacts.org/blog/weight

    #Health #Obesity #HealthCare

  14. Enveda Moves Ahead To Address Post-GLP-1 Weight Loss Maintenance – insights.citeline.com

    Enveda Moves Ahead To Address Post-GLP-1 Weight Loss Maintenance  insights.citeline.comA pill that mimics exercise? Early results on drug designed…
    #NewsBeep #News #Medication #ClinicalTrials #Health #Metabolicdisorders #Obesity #Research&Development #UK #UnitedKingdom
    newsbeep.com/uk/743647/

  15. An ‘Exercise Pill’ Just Cleared Its First Human Test

    Scientists might be inching closer to a breakthrough that some of us lazy bums would very much appreciate:…
    #NewsBeep #News #Health #exercise #experimentalresearch #GB #Obesity #UK #UnitedKingdom
    newsbeep.com/uk/743481/

  16. An ‘Exercise Pill’ Just Cleared Its First Human Test

    Scientists might be inching closer to a breakthrough that some of us lazy bums would very much appreciate:…
    #NewsBeep #News #Fitness #AU #Australia #Exercise #experimentalresearch #Health #Obesity
    newsbeep.com/au/861352/

  17. An ‘Exercise Pill’ Just Cleared Its First Human Test

    Scientists might be inching closer to a breakthrough that some of us lazy bums would very much appreciate:…
    #NewsBeep #News #Fitness #AU #Australia #Exercise #experimentalresearch #Health #Obesity
    newsbeep.com/au/861352/

  18. An ‘Exercise Pill’ Just Cleared Its First Human Test

    Scientists might be inching closer to a breakthrough that some of us lazy bums would very much appreciate:…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Fitness #exercise #experimentalresearch #Health #Obesity
    newsbeep.com/us/819241/

  19. Amylyx endocrine drug succeeds in key study for low blood sugar

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #biotechnology #drugdevelopment #Health #Obesity #Research #STAT+
    newsbeep.com/us/817717/

  20. Amylyx endocrine drug succeeds in key study for low blood sugar

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #biotechnology #drugdevelopment #Health #Obesity #Research #STAT+
    newsbeep.com/us/817717/

  21. Amylyx endocrine drug succeeds in key study for low blood sugar

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
    #NewsBeep #News #Medication #AU #Australia #Biotechnology #drugdevelopment #Health #Obesity #research #STAT+
    newsbeep.com/au/859679/

  22. Amylyx endocrine drug succeeds in key study for low blood sugar

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
    #NewsBeep #News #Medication #AU #Australia #Biotechnology #drugdevelopment #Health #Obesity #research #STAT+
    newsbeep.com/au/859679/

  23. Enveda weight loss maintenance pill mimics exercise in early tests

    If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you…
    #NewsBeep #News #Medication #Biotech #cardiovasculardisease #chronicdiseases #drugdevelopment #Health #Obesity #Pharmaceuticals #STAT+ #UK #UnitedKingdom
    newsbeep.com/uk/741857/

  24. Enveda weight loss maintenance pill mimics exercise in early tests

    If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you…
    #NewsBeep #News #Medication #AU #Australia #Biotech #CardiovascularDisease #chronicdiseases #drugdevelopment #Health #Obesity #Pharmaceuticals #STAT+
    newsbeep.com/au/859593/

  25. Enveda weight loss maintenance pill mimics exercise in early tests

    If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you…
    #NewsBeep #News #Medication #AU #Australia #Biotech #CardiovascularDisease #chronicdiseases #drugdevelopment #Health #Obesity #Pharmaceuticals #STAT+
    newsbeep.com/au/859593/

  26. ‘A tax on being thin’: only high earners make overall savings on food bills from weight-loss drugs
    By Zoe Wood

    Users need discretionary income of nearly £100,000 a year to make savings on their grocery spend after paying £1,200 for GLP-1s, analysis finds

    theguardian.com/science/2026/a

    #Weightlossdrugs #Inequality #Science #Pharmaceuticalsindustry #Business #Health #Society #UKnews #Obesity #NHS #Privatehealthcare #TheGuardian #ZoeWood

  27. ‘A tax on being thin’: only high earners make overall savings on food bills from weight-loss drugs
    By Zoe Wood

    Users need discretionary income of nearly £100,000 a year to make savings on their grocery spend after paying £1,200 for GLP-1s, analysis finds

    theguardian.com/science/2026/a

    #Weightlossdrugs #Inequality #Science #Pharmaceuticalsindustry #Business #Health #Society #UKnews #Obesity #NHS #Privatehealthcare #TheGuardian #ZoeWood

  28. ‘A tax on being thin’: only high earners make overall savings on food bills from weight-loss drugs
    By Zoe Wood

    Users need discretionary income of nearly £100,000 a year to make savings on their grocery spend after paying £1,200 for GLP-1s, analysis finds

    theguardian.com/science/2026/a

    #Weightlossdrugs #Inequality #Science #Pharmaceuticalsindustry #Business #Health #Society #UKnews #Obesity #NHS #Privatehealthcare #TheGuardian #ZoeWood